What is King Pharmaceuticals's all other lines — year 6?

King Pharmaceuticals (KG) reported all other lines — year 6 of -0.9% in Q4 2025.

What does all other lines — year 6 mean?

This metric captures the financial performance of non-core business segments and miscellaneous product lines during the sixth fiscal year. It provides visibility into the revenue and operational impact of secondary activities that fall outside the primary reporting structure. Investors use this to evaluate the performance of the company's peripheral business interests.

King Pharmaceuticals KG All other lines — Year 6

Other product segments

General Liability

10.8%—

Commercial Auto Liability

8.6%—

European Hospital Liability

8.5%—

International

0.7%—

Similar metrics at other companies

GLREFinancial — Year 6

11.8%—

SPNTOther — Year 6

1%-0.1pp

ACGLMulti-line and other specialty — Year Six

3.7%+0.4pp

SPNTOther Specialties — Year 6

1.4%+0.5pp

SPNTOther — Year 10

0%—

UFCSPersonal — Year 6

0.3%-0.1pp

Other financials

Income statement

See full

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Balance sheet

See full

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Cash flow

See full

Operating cash flow-$15.1M-1,628%

Valuation

See full

Market cap$70.42M-67.6%

Enterprise value$184.93M-50.0%

P/E1.2×—

P/S1.6×-24.3×

Profitability

See full

Net margin131.5%—

Returns & leverage

See full

Return on equity90.8%—

Debt / equity1.5×—

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ShortdurationInsuranceContractsHistoricalClaimsDurationYearSix.

The official record: King Pharmaceuticals’s 10-K, filed March 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's all other lines — year 6.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is King Pharmaceuticals's all other lines — year 6?: King Pharmaceuticals (KG) reported all other lines — year 6 of -0.9% in Q4 2025.
What does all other lines — year 6 mean?: This metric captures the financial performance of non-core business segments and miscellaneous product lines during the sixth fiscal year. It provides visibility into the revenue and operational impact of secondary activities that fall outside the primary reporting structure. Investors use this to evaluate the performance of the company's peripheral business interests.